GE Healthcare's research and development is centered on AI, as explained by the CEO.

• Arduini discussed with Cramer the development of AI products at GE Healthcare, including technology to unify patient data.
• Advanced technology can also be enhanced by AI, and customers are willing to pay for it, according to Arduini.

In a Thursday interview with CNBC's Jim Cramer, CEO Peter Arduini revealed that much of his company's research and development efforts are geared towards artificial intelligence.

Arduini explored various ways AI can improve the efficiency of healthcare workers by streamlining patient data.

The final component, currently being assembled and set to develop over the next few years, is known as multimodal data integration. This involves combining genomics, pathology, and image data on a single dashboard, with an algorithm or foundational model that can interpret the data and guide clinicians in making informed decisions.

Arduini stated that AI can enhance imaging in MRIs, CTs, and ultrasounds, and that customers are willing to pay more for these advanced products. He also mentioned that GE Healthcare's R&D investments over the past year resulted in a pipeline of 40 new products that will positively impact the business.

GE Healthcare's first year as an independent company allowed for advancement, according to Arduini's reflection.

Our board is highly focused, and we attract individuals who are deeply committed to healthcare. As a result, we have been able to allocate our resources more effectively across the company.

Join the CNBC Investing Club to receive updates on Jim Cramer's market moves.

Disclaimer The CNBC Investing Club Charitable Trust holds shares of GE Healthcare.